MXPA04005992A - Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa. - Google Patents
Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa.Info
- Publication number
- MXPA04005992A MXPA04005992A MXPA04005992A MXPA04005992A MXPA04005992A MX PA04005992 A MXPA04005992 A MX PA04005992A MX PA04005992 A MXPA04005992 A MX PA04005992A MX PA04005992 A MXPA04005992 A MX PA04005992A MX PA04005992 A MXPA04005992 A MX PA04005992A
- Authority
- MX
- Mexico
- Prior art keywords
- molecule
- modified
- therapeut
- nucleic acid
- acid encoding
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 230000005867 T cell response Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000002650 immunosuppressive therapy Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104333A SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
| PCT/GB2002/005743 WO2003051826A1 (en) | 2001-12-19 | 2002-12-18 | 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04005992A true MXPA04005992A (es) | 2004-09-27 |
Family
ID=20286432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04005992A MXPA04005992A (es) | 2001-12-19 | 2002-12-18 | Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7276539B2 (https=) |
| EP (1) | EP1458677B1 (https=) |
| JP (2) | JP3810770B2 (https=) |
| KR (1) | KR20040068589A (https=) |
| CN (1) | CN100343229C (https=) |
| AR (1) | AR038046A1 (https=) |
| AT (1) | ATE428691T1 (https=) |
| AU (1) | AU2002352426A1 (https=) |
| BR (1) | BR0215090A (https=) |
| CA (1) | CA2470066C (https=) |
| CO (1) | CO5590908A2 (https=) |
| DE (1) | DE60232018D1 (https=) |
| ES (1) | ES2324025T3 (https=) |
| HU (1) | HUP0402093A3 (https=) |
| IL (1) | IL162378A0 (https=) |
| IS (1) | IS7303A (https=) |
| MX (1) | MXPA04005992A (https=) |
| NO (1) | NO20043084L (https=) |
| NZ (1) | NZ533365A (https=) |
| PL (1) | PL370623A1 (https=) |
| RU (1) | RU2004117776A (https=) |
| SE (1) | SE0104333D0 (https=) |
| TW (1) | TW200410678A (https=) |
| UA (1) | UA80407C2 (https=) |
| WO (1) | WO2003051826A1 (https=) |
| ZA (1) | ZA200404585B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0311932A (pt) | 2002-06-20 | 2005-03-22 | Astrazeneca Ab | Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado |
| GB0314130D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314075D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314131D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314134D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314260D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0427524D0 (en) | 2004-12-16 | 2005-01-19 | Astrazeneca Ab | Chemical process |
| GB0427701D0 (en) * | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Therapeutic agents |
| RU2480453C2 (ru) | 2007-03-08 | 2013-04-27 | Альбирео Аб | Новые соединения |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| US5232945A (en) * | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
| AU1903799A (en) | 1997-12-05 | 1999-06-28 | Eisai Co. Ltd. | Compositions and methods for modulating the activity of fibroblast growth factor |
| ATE451346T1 (de) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| SE9801990D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl propionic acid derivatives and analogs |
| MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
| GB9822473D0 (en) * | 1998-10-16 | 1998-12-09 | Glaxo Group Ltd | Chemical compounds |
| YU72201A (sh) * | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| TW574193B (en) | 1999-12-03 | 2004-02-01 | Astrazeneca Ab | Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses |
| SE9904421D0 (sv) | 1999-12-03 | 1999-12-03 | Astra Ab | New compounds |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| IL151517A0 (en) | 2000-03-09 | 2003-04-10 | Aventis Pharma Gmbh | Therapeutic uses of ppar mediators |
| SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| SE0101978D0 (sv) | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | New compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) * | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| AU2002329387B2 (en) | 2001-09-08 | 2007-06-07 | Albireo Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia |
| SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| SE0201936D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| SE0201937D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| BR0311932A (pt) | 2002-06-20 | 2005-03-22 | Astrazeneca Ab | Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314078D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314131D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314130D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314075D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314136D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314260D0 (en) | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2001
- 2001-12-19 SE SE0104333A patent/SE0104333D0/xx unknown
-
2002
- 2002-12-18 IL IL16237802A patent/IL162378A0/xx unknown
- 2002-12-18 CA CA002470066A patent/CA2470066C/en not_active Expired - Fee Related
- 2002-12-18 UA UA20040604534A patent/UA80407C2/uk unknown
- 2002-12-18 CN CNB028281225A patent/CN100343229C/zh not_active Expired - Fee Related
- 2002-12-18 WO PCT/GB2002/005743 patent/WO2003051826A1/en not_active Ceased
- 2002-12-18 KR KR10-2004-7009348A patent/KR20040068589A/ko not_active Withdrawn
- 2002-12-18 TW TW091136517A patent/TW200410678A/zh unknown
- 2002-12-18 AT AT02788144T patent/ATE428691T1/de not_active IP Right Cessation
- 2002-12-18 PL PL02370623A patent/PL370623A1/xx unknown
- 2002-12-18 DE DE60232018T patent/DE60232018D1/de not_active Expired - Lifetime
- 2002-12-18 AU AU2002352426A patent/AU2002352426A1/en not_active Abandoned
- 2002-12-18 EP EP02788144A patent/EP1458677B1/en not_active Expired - Lifetime
- 2002-12-18 RU RU2004117776/04A patent/RU2004117776A/ru not_active Application Discontinuation
- 2002-12-18 US US10/499,042 patent/US7276539B2/en not_active Expired - Fee Related
- 2002-12-18 NZ NZ533365A patent/NZ533365A/en unknown
- 2002-12-18 BR BR0215090-5A patent/BR0215090A/pt not_active IP Right Cessation
- 2002-12-18 HU HU0402093A patent/HUP0402093A3/hu unknown
- 2002-12-18 MX MXPA04005992A patent/MXPA04005992A/es not_active Application Discontinuation
- 2002-12-18 JP JP2003552714A patent/JP3810770B2/ja not_active Expired - Fee Related
- 2002-12-18 ES ES02788144T patent/ES2324025T3/es not_active Expired - Lifetime
- 2002-12-19 AR ARP020105003A patent/AR038046A1/es not_active Application Discontinuation
-
2004
- 2004-06-08 IS IS7303A patent/IS7303A/is unknown
- 2004-06-09 ZA ZA200404585A patent/ZA200404585B/en unknown
- 2004-07-16 CO CO04068143A patent/CO5590908A2/es not_active Application Discontinuation
- 2004-07-16 NO NO20043084A patent/NO20043084L/no not_active Application Discontinuation
-
2006
- 2006-03-20 JP JP2006077296A patent/JP2006241162A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005511785A (ja) | 2005-04-28 |
| PL370623A1 (en) | 2005-05-30 |
| US20050215630A1 (en) | 2005-09-29 |
| JP3810770B2 (ja) | 2006-08-16 |
| EP1458677B1 (en) | 2009-04-15 |
| EP1458677A1 (en) | 2004-09-22 |
| JP2006241162A (ja) | 2006-09-14 |
| ES2324025T3 (es) | 2009-07-29 |
| NZ533365A (en) | 2006-05-26 |
| IS7303A (is) | 2004-06-08 |
| HK1068866A1 (en) | 2005-05-06 |
| BR0215090A (pt) | 2004-11-16 |
| KR20040068589A (ko) | 2004-07-31 |
| ATE428691T1 (de) | 2009-05-15 |
| AU2002352426A1 (en) | 2003-06-30 |
| IL162378A0 (en) | 2005-11-20 |
| DE60232018D1 (de) | 2009-05-28 |
| CA2470066A1 (en) | 2003-06-26 |
| HUP0402093A3 (en) | 2008-08-28 |
| CN100343229C (zh) | 2007-10-17 |
| AR038046A1 (es) | 2004-12-22 |
| US7276539B2 (en) | 2007-10-02 |
| HUP0402093A2 (hu) | 2005-02-28 |
| ZA200404585B (en) | 2005-10-26 |
| CA2470066C (en) | 2007-04-10 |
| WO2003051826A1 (en) | 2003-06-26 |
| UA80407C2 (en) | 2007-09-25 |
| CN1620430A (zh) | 2005-05-25 |
| CO5590908A2 (es) | 2005-12-30 |
| TW200410678A (en) | 2004-07-01 |
| RU2004117776A (ru) | 2006-01-10 |
| SE0104333D0 (sv) | 2001-12-19 |
| NO20043084L (no) | 2004-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1548032T3 (da) | KDR-peptider og vacciner indeholdende disse | |
| WO2005005462A3 (en) | Blys antagonists and uses thereof | |
| MXPA03002572A (es) | Secuencias de nucleotidos que intervienen en la fertilidad de los machos y metodo de su uso. | |
| TW200635946A (en) | Binding proteins specific for human matriptase | |
| MXPA04005992A (es) | Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa. | |
| MXPA03006984A (es) | Secuencia de nucleotidos que median la fertilidad masculina y metodo de uso de la misma. | |
| EP1100815A4 (en) | PROTEASE TYPE II CLEAVABLE PEPTIDE | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| WO2002102852A3 (en) | Modified cd8 molecule, nucleic acid encoding said molecule, and their therapeut ic use | |
| ATE521702T1 (de) | Krebsantigene und deren nutzung | |
| GB0418388D0 (en) | Cell therapy | |
| GB0123664D0 (en) | Histone deacetylase 9 | |
| IL149416A0 (en) | Human enzymes of the metalloprotease family | |
| DK1051491T3 (da) | Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf | |
| ATE291621T1 (de) | Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen | |
| FR2792651B1 (fr) | Sequence genomique et polypeptides de pyrococcus abyssi, leurs fragments et leurs utilisations | |
| WO2005000870A3 (en) | Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof | |
| SG161106A1 (en) | Inhibitor proteins of a protease and use thereof | |
| PL374550A1 (en) | Il-17 like molecules and uses thereof | |
| WO2003066879A3 (en) | Amino acid transporters | |
| DK0811068T3 (da) | Humane DNase I varianter | |
| KR20040053279A (ko) | 스트레스 저항성 및 내성 단백질을 코딩하는 유전자 | |
| EP1191096A4 (en) | NEW PROTEIN AND ITS DNA | |
| WO2005060667A3 (en) | Nucleic acid and amino acid sequences involved in pain | |
| WO2004078776A3 (en) | Ny-eso-1 peptides which bind to class ii molecules and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |